Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6, 1999, Pages 331-339

  Avellone, G ^a,b   Di Garbo, V ^a   Abruzzese, G ^a   Campisi, D ^a   Giannola, G ^a   De Simone, R ^a   Raneli, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Carotid atherosclerotic lesions; Coagulation; Fibrinolysis, Lp(a); Myocardial infarction

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; THROMBIN ANTITHROMBIN COMPLEX; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; INTIMA; LIPOPROTEIN BLOOD LEVEL; MALE; PATHOGENESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VEIN OCCLUSION;

EID: 0032869001     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199909000-00003     Document Type: Article

References (60)

1. 1. Strano A, Davi G, Novo S, Avellone G. Thrombophilic states and atherosclerosis. In: Crepaldi G, Fellin R, Olsson AG, Toffano G (editors): Arteriosclerosis brain disease. New York: Raven Press; 1983. pp. 173-180.
2. 2. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using marker of the hemostatic system activation. Blood 1987; 70: 343-350.
3. 3. Speiser W, Speiser P, Minar E, Korninger C, Niessner H, Huber K, et al. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: relation to localization of vessel disease and risk factors. Thromb Res 1990; 59: 77-88.
4. 4. Panchenko E, Dobrovolsky A, Davletov K, Titaeva E, Kravets A, Podinovskaya J, et al. D-Dimer and fibrinolysis in patients with various degrees of atherosclerosis. Eur Heart J 1995; 16: 38-42.
5. 5. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larson B, Welin I., Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
6. 6. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
7. 7. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, De Gaetano G, et al. The PLAT study. Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12: 1063-1070.
8. 8. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 41: 1165-1168.
9. 9. Semeraro N. I meccanismi emostatici: implicazioni per la fisiopatologia della trombosi arteriosa e dell'aterosclerosi. G Arterioscler 1993; 18 (suppl): 5-18.
10. 10. Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990; 10: 1-7.
11. 11. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
12. 12. Davies MJ, Thomas AC. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140.
13. 13. Smith EB, Keene GA, Grant A, Stirk G. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-274.
14. 14. Tanaka M, Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. Thromb Res 1994; 76: 289-298.
15. 15. Juhan-Vague I, Aillaud MF, Valadier J, Alessi MC, Serradimigni A. Thromboembolic disease and anomalies of fibrinolysis. Ann Med Interne 1986; 137: 471-474.
16. 16. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitors and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1991; 12: 157-161.
17. 17. Novo S, Abrignani MG, Liquori M, Sanguigni V, Barbagallo M, Longo B, et al. Arteriopatia carotidea e degli arti inferiori in soggetti con cardiopatia ischemica: aspetti diagnostici e problemi clinici. Cardiologia 1992; 37 (suppl 1): 337-350.
18. 18. Spurk P, Angelkort B, Selter P. Incidence of arteriosclerotic lesions of carotid arteries in chronic peripheral arterial disease and myocardial infarction. Angiology 1989; 40: 39-44.
19. 19. Craven TE, Ryu JE, Espeland HA. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case control study. Circulation 1990; 82: 1230-1242.
20. 20. Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 1991; 11: 1786-1794.
21. 21. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-269.
22. 22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1403.
23. 23. Seifert S, Kazatchkine MD. The complement system and atherosclerosis. Atherosclerosis 1988; 73: 91-104.
24. 24. Neri Serneri GG. Coronary thrombosis: plaque rupture or acute inflammatory reaction? In: Neri Serneri GG, Gensini GF, Abbate R, Prisco D (editors): Atherosclerosis inflammation and thrombosis. Florence, Italy: Scientific Press; 1993. pp. 185-200.
25. 25. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13: 1829-1836.
26. 26. Hamsten A, de Faire U, Walldius G, Dahln G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 330: 3-9.
27. 27. Jansson J-H, Olofsson B-O, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034.
28. 28. Glueck CJ, Rorick MH, Schmerler M, Anthony J, Feibel J, Bashir M, et al. Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125: 319-325.
29. 29. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-1365.
30. 30. Ceriello A, Taboga C, Giacomello R, Falleti E, De Stasio G, Motz E, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994; 43: 430-432.
31. 31. Hoek YA, Sturk A, Ten Cate JW, Lamping RJ, Berends F, Borm JJJ. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III (TAT) complexes in plasma. Clin Chem 1988; 34: 2058-2062.
32. 32. Marder SR, Chenoweth DE, Goldestein M, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a desArg. J Immunol 1985; 134: 3325-3331.
33. 33. Mennen LI, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review. Thromb Haemost 1996; 76: 492-499.
34. 34. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, et al. Association between dietary fat intake and plasma factor VII coagulant activity. Atherosclerosis 1986; 60: 269-277.
35. 35. Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, Sirtori CR. Increased platelet sensitivity and thromboxane formation in type II hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-333.
36. 36. Davì G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798.
37. 37. Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-790.
38. 38. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, et al. Hypertriglyceridemia and regulation of fibrinolytic activicy. Arterioscler Thromb 1992; 12: 19-27.
39. 39. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani GD. Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion. Blood Coag Fibrinol 1993; 4: 429-433.
40. 40. Mitropoulos KA, Miller GJ, Wats GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 1992; 95: 119-125.
41. 41. Muscari A, Bozzoli C, Gerratana C, Zacà F, Rovinetti C, Zauli D, et al. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis 1988; 74: 179-186.
42. 42. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, et al. Association of scrum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-364.
43. 43. Rapaport SI, Rao VM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121.
44. 44. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO III. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90: 35-41.
45. 45. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 14: 488-500.
46. 46. Siess W. Molecular mechanism of platelet activation. Physiol Rev 1989; 69: 58-178.
47. 47. Jennings I, Luddington RJ, Harper PL. Changes in endothelial-related coagulation proteins in response to venous occlusion. Thromb Haemost 1991; 65: 374-376.
48. 48. Sawa H, Sobel BE, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res 1993; 73: 671-680.
49. 49. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
50. 50. Avellone G, Di Garbo V, Cordova R, Abruzzese G, Rotolo G, Raneli G, et al. Activation of coagulation but normal fibrinolysis in patients with type IIa hyperlipoproteinemia. Thromb Res 1996; 81: 277-282.
51. 51. Chin JB, Azhar S, Hoffmann BB. Inactivation of endothelial derived relaxing factor by oxidized LDL. J Clin Invest 1992; 89: 10-18.
52. 52. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R. Antibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
53. 53. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991; 115: 209-218.
54. 54. Matsumoto T, Fujiokka T, Saito E, Kanmatsuse K. Lipoprotein(a) as a risk factor for cerebrovascular disease and dementia. Nutr Met Cardiovasc Dis 1995; 5: 17-22.
55. 55. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-2465.
56. 56. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14: 438-442.
57. 57. Alessi MC, Parra HJ, Joly P, Vu-Dac N, Bard JM, Fruchart JC, et al. The increased plasma Lp(a):β lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. Clin Chim Acta 1990; 188: 119-128.
58. 58. Heinrich J, Sandkamp M, Kokott R, Shultz H, Assmann G. Relationships of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950-1954.
59. 59. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993; 42: 236-246.
60. 60. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD, et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993; 88: 935-940.